[ad_1]
Dr. Nader Pourhbadan, CEO of CytoDyn Inc. (OTCMKTS: CYDY), tells Proactive Investors that biotechnology has signed an exclusive worldwide licensing agreement with IncellDX, a cellular diagnostic company, positioning CytoDyn to generate its first-ever revenue. business in the coming months
Pourhbadan also explains the recent departure of Dr. Richard Pestell, former Chief Medical Officer, and what it means for the future clinical development by CytoDyn of leronlimab (PRO 140) in the treatment of cancer and immunology.
Source link
